Conferences like the Biotech Showcase are fantastic for gaining international exposure, and most likely will increase receptiveness of Cardiocel by cardiothoracic surgeons/hospitals in the U.S./worldwide. The proven success of Cardiocel should value the *current* share price around 20cps (imo) - this should be boosted with international uptake and FDA approval in the U.S, and even further by regulatory approval of a similar ADAPT-based scaffold for hernia repair next year.
This is assuming that the HSV trial isn't even mentioned during the showcase - a significant re-rating (up) seems likely with even a drift of positive results.
We aren't known as the 'clever country' for nothing ;)
how far can we go? , page-32
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.91 |
Change
-0.090(0.50%) |
Mkt cap ! $344.2M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.75 | $74.32K | 4.151K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 681 | $17.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.25 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |